Biomarkers For Rare Diseases Get Scaled-Back Plea In New White Paper

EveryLife Foundation’s finalized white paper on using accelerated approval in rare diseases indicates that biomarkers don’t have to be discussed with FDA at the pre-IND stage, but should be done early enough to allow development process predictability.